等待開盤
0.000
NaN.00%
Entrada Therapeutics appoints Dr. Maha Radhakrishnan to its Board of Directors to leverage her expertise in drug development, particularly for advancing Duchenne muscular dystrophy programs into clinical trials. Dr. Radhakrishnan brings extensive experience from roles at Sofinnova Investments, Biogen, and Sanofi, and her leadership will support Entrada’s innovative intracellular therapies.
2025-06-03 11:00